SC10914 / Jiangxi Qingfeng Pharma, Shanghai De Novo Pharmatech - LARVOL DELTA

[VIRTUAL] Phase I study to assess the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of SC10914 in patients with advanced solid tumors. (ASCO 2020) - P1 | "SC10914 has a similar structure with olaparib. SC10914 was safe in patients with advanced solid tumors. The main toxicity was blood-related adverse reactions. SC10914 was effective in gBRCAm ovarian cancer patients."

Clinical • P1 data • PK/PD data • Gynecologic Cancers • Hematological Disorders • Neutropenia • Oncology • Ovarian Cancer • Solid Tumor • Thrombocytopenia • CA125 • PARP • PARP1

Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer (clinicaltrials.gov) - P2; N=104; Recruiting; Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Monotherapy • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients (clinicaltrials.gov) - P2; N=78; Recruiting; Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Clinical • New P2 trial • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2

Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer (clinicaltrials.gov) - P2; N=104; Not yet recruiting; Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Clinical • Monotherapy • New P2 trial • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2

SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation (clinicaltrials.gov) - P1/2; N=90; Not yet recruiting; Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Clinical • Monotherapy • New P1/2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA

A Study of SC10914 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Clinical • New P1 trial